Literature DB >> 24776539

Isolation and characterization of the circulating truncated form of PCSK9.

Bomie Han1, Patrick I Eacho1, Michael D Knierman1, Jason S Troutt1, Robert J Konrad1, Xiaohong Yu1, Krista M Schroeder1.   

Abstract

Proprotein convertase subtilisin-kexin type 9 (PCSK9) is a secreted protein which regulates serum LDL cholesterol. It circulates in human and rodent serum in an intact form and a major truncated form. Previous in vitro studies involving the expression of human PCSK9 genetic variants and in vivo studies of furin knockout mice suggest that the truncated form is a furin cleavage product. However, the circulating truncated form of PCSK9 has not been isolated and characterized. Utilizing antibodies which bind to either the catalytic domain or the C-terminal domain of PCSK9, the truncated PCSK9 was isolated from serum. MS was used to determine that this form of PCSK9 is a product of in vivo cleavage at Arg218 resulting in pyroglutamic acid formation of the nascent N terminus corresponding to Gln219 of intact PCSK9. We also determined that the truncated PCSK9 in serum lacked the N-terminal segment which contains amino acids critical for LDL receptor binding. A truncated PCSK9, expressed and purified from HEK293 cells with identical composition as the circulating truncated protein, was not active in inhibition of LDL uptake by HepG2 cells. These studies provide a definitive characterization of the composition and activity of the truncated form of PCSK9 found in human serum.
Copyright © 2014 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  furin; low density lipoprotein cholesterol; low density lipoprotein receptor; monoclonal antibodies; proprotein convertase subtilisin-kexin type 9; proteolytic cleavage

Mesh:

Substances:

Year:  2014        PMID: 24776539      PMCID: PMC4076096          DOI: 10.1194/jlr.M049346

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  43 in total

Review 1.  Molecular biology of PCSK9: its role in LDL metabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Trends Biochem Sci       Date:  2007-01-09       Impact factor: 13.807

2.  Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

Authors:  Kara N Maxwell; Edward A Fisher; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-27       Impact factor: 11.205

3.  Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

Authors:  Thomas A Lagace; David E Curtis; Rita Garuti; Markey C McNutt; Sahng Wook Park; Heidi B Prather; Norma N Anderson; Y K Ho; Robert E Hammer; Jay D Horton
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

4.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

5.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

6.  Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.

Authors:  Timothy S Fisher; Paola Lo Surdo; Shilpa Pandit; Marco Mattu; Joseph C Santoro; Doug Wisniewski; Richard T Cummings; Alessandra Calzetta; Rose M Cubbon; Paul A Fischer; Anil Tarachandani; Raffaele De Francesco; Samuel D Wright; Carl P Sparrow; Andrea Carfi; Ayesha Sitlani
Journal:  J Biol Chem       Date:  2007-05-10       Impact factor: 5.157

7.  Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice.

Authors:  Kara N Maxwell; Raymond E Soccio; Elizabeth M Duncan; Ephraim Sehayek; Jan L Breslow
Journal:  J Lipid Res       Date:  2003-08-01       Impact factor: 5.922

8.  Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

Authors:  Holly E Careskey; R Aleks Davis; William E Alborn; Jason S Troutt; Guoqing Cao; Robert J Konrad
Journal:  J Lipid Res       Date:  2007-11-21       Impact factor: 5.922

9.  Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.

Authors:  Robert J Schmidt; Thomas P Beyer; William R Bensch; Yue-Wei Qian; Aiming Lin; Mark Kowala; William E Alborn; Robert J Konrad; Guoqing Cao
Journal:  Biochem Biophys Res Commun       Date:  2008-04-10       Impact factor: 3.575

10.  Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.

Authors:  Markey C McNutt; Thomas A Lagace; Jay D Horton
Journal:  J Biol Chem       Date:  2007-05-29       Impact factor: 5.157

View more
  24 in total

Review 1.  PCSK9 in chronic kidney disease.

Authors:  P Pavlakou; E Liberopoulos; E Dounousi; M Elisaf
Journal:  Int Urol Nephrol       Date:  2017-01-13       Impact factor: 2.370

2.  Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.

Authors:  Sergio Fazio; Jessica Minnier; Michael D Shapiro; Sotirios Tsimikas; Patrizia Tarugi; Maurizio R Averna; Marcello Arca; Hagai Tavori
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

3.  Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).

Authors:  Ali Ben Djoudi Ouadda; Marie-Soleil Gauthier; Delia Susan-Resiga; Emmanuelle Girard; Rachid Essalmani; Miles Black; Jadwiga Marcinkiewicz; Diane Forget; Josée Hamelin; Alexandra Evagelidis; Kevin Ly; Robert Day; Luc Galarneau; Francois Corbin; Benoit Coulombe; Artuela Çaku; Vincent S Tagliabracci; Nabil G Seidah
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-05       Impact factor: 8.311

Review 4.  Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

Authors:  Giuseppe Danilo Norata; Hagai Tavori; Angela Pirillo; Sergio Fazio; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2016-08-05       Impact factor: 10.787

5.  Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody.

Authors:  Krista M Schroeder; Thomas P Beyer; Ryan J Hansen; Bomie Han; Richard T Pickard; Victor J Wroblewski; Mark C Kowala; Patrick I Eacho
Journal:  J Lipid Res       Date:  2015-09-20       Impact factor: 5.922

6.  High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels.

Authors:  Bin Dong; Amar Bahadur Singh; Salman Azhar; Nabil G Seidah; Jingwen Liu
Journal:  Atherosclerosis       Date:  2015-01-30       Impact factor: 5.162

Review 7.  PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9.

Authors:  Hagai Tavori; Ilaria Giunzioni; Sergio Fazio
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-04       Impact factor: 3.243

Review 8.  On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.

Authors:  Hagai Tavori; Shirya Rashid; Sergio Fazio
Journal:  Atherosclerosis       Date:  2014-12-17       Impact factor: 5.162

Review 9.  How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?

Authors:  Yu Kataoka; Sayaka Funabashi; Takahito Doi; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2022-01-13       Impact factor: 4.394

Review 10.  The Multifaceted Biology of PCSK9.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Endocr Rev       Date:  2022-05-12       Impact factor: 25.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.